Positron emission tomography (PET) with fluorine-18-2-D-deoxyglucose (
FDG) currently is being integrated into clinical oncology because it p
rovides unique functional information that can be applied to the manag
ement of cancer. In particular, it is useful for assessing tumor activ
ity and growth, evaluating efficacy of therapy, and detecting tumor re
currence. Studies have demonstrated the value of whole-body PET-FDG im
aging when staging and managing abdominal malignancy.